Loading stock data…
Tenax Therapeutics (TENX)
$14.53-0.11 (-0.75%)
Market ClosedLast close Jul 24
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tenax Therapeutics, Inc. in the Healthcare sector is trading at $14.53 with a market capitalization of $299M. Wall Street consensus targets $35.22 (9 analysts), implying a +142.4% move over the next 12 months. The stock is currently 25% below its 52-week high of $19.40, remaining 20.5% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +142.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$16.57M↓ | -$16.45M↑ | -$16.81M↓ | -$11.79M↓ | -$11.34M |
| Net Income | -$15.72M↓ | -$15.54M↑ | -$15.80M↓ | -$10.85M↓ | -$10.41M |
Peer Comparison
JNJUNHPFE
Fundamentals
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatme...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$299.20M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-50.49%
Volume
Today's trading volume
1.16M
Recent News
Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know
The mean of analysts' price targets for Tenax Therapeutics (TENX) points to a 121.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Set to Open Higher in Thursday Trading; US Adds Only 57,000 Jobs in June
US stocks look set to open higher in Thursday's trading session as investors parse key employment da
Companies Like Tenax Therapeutics (NASDAQ:TENX) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. By way of example, Tenax Therapeutics...
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
Tenax Therapeutics: Q4 Earnings Snapshot
The Chapel Hill, North Carolina-based company said it had a loss of 38 cents per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.26 per share.